Skip to Content

OncoSec Medical Inc ONCSQ

Morningstar Rating
$0.00 0.00 (50.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ONCSQ is trading at a 53% discount.
Price
$0.00
Fair Value
$8.26
Uncertainty
Extreme
1-Star Price
$8.39
5-Star Price
$8.40
Economic Moat
Dlgb
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ONCSQ is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.001.31
Bid/Ask
$0.02 / $0.03
Market Cap
$1,788.77
Volume/Avg
410 / 6,352

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
41

Valuation

Metric
ONCSQ
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ONCSQ
Quick Ratio
0.51
Current Ratio
0.89
Interest Coverage
−626.66
Quick Ratio
ONCSQ

Profitability

Metric
ONCSQ
Return on Assets (Normalized)
−130.07%
Return on Equity (Normalized)
−733.19%
Return on Invested Capital (Normalized)
−234.34%
Return on Assets
ONCSQ
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWbrpxmbsTvps$567.0 Bil
VRTX
Vertex Pharmaceuticals IncKnjzsfknHqpkyrf$105.9 Bil
REGN
Regeneron Pharmaceuticals IncJntvzwdRnszky$105.3 Bil
MRNA
Moderna IncBvvhtbjGww$46.7 Bil
ARGX
argenx SE ADRJlmbflsvkZjny$23.5 Bil
BNTX
BioNTech SE ADRVjhynrthZhy$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncYsxrwrsNzmjm$19.3 Bil
BMRN
Biomarin Pharmaceutical IncGjyjjvxtDmtrdbm$15.5 Bil
RPRX
Royalty Pharma PLC Class AZdrbzbjnqqTtxvbz$12.6 Bil
INCY
Incyte CorpRvzynfpjhKdhmcq$12.0 Bil

Sponsor Center